NCT03619902View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

January 20, 2021

Study Completion Date

January 20, 2021

Conditions
Generalized Pustular Psoriasis
Interventions
BIOLOGICAL

Imsidolimab

Humanized monoclonal antibody

Trial Locations (13)

33316

Site 104, Miami

33771

Site 105, Largo

46250

Site 101, Indianapolis

48109

Site 100, Ann Arbor

91436

Site 102, Encino

90-436

Site 303, Lodz

Unknown

Site 302, Lodz

Site 201, London

Site 203, Newcastle upon Tyne

Site 202, Salford

10-229

Site 304, Olsztyn

35-055

Site 301, Rzeszów

03722

Site 501, Seoul

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY